Tadocizumab

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]

Tadocizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetIntegrin αIIbβ3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC2107H3252N562O673S12
Molar mass47609.17 g·mol−1
 NY (what is this?)  (verify)

The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
  2. Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.